InVivo Therapeutics Development Portfolio

InVivo Therapeutics is focused on utilizing polymers as a platform technology to develop and commercialize groundbreaking treatments for spinal cord injuries (SCI). InVivo’s technologies encompasses multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs).

Background

InVivo’s proprietary technology was co-invented by Robert S. Langer, ScD, the David H. Koch Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, affiliated with Massachusetts General Hospital. The patent rights that are the basis for InVivo’s products are under an exclusive, worldwide license from Children’s Medical Center Corporation and Massachusetts Institute of Technology.

Data on InVivo’s technology was first published in PNAS in 2002 and has since been demonstrated to successfully promote functional recovery following traumatic spinal cord injury in several models including rodent and non-human primate models. Data from InVivo’s pilot non-human primate study was published in the Journal of Neuroscience Methods in 2010.